<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" VersionID="2" Owner="NLM" IndexingMethod="Automated"><PMID Version="2">36786873</PMID><DateCompleted><Year>2023</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2023</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1437-160X</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>7</Issue><PubDate><Year>2023</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Rheumatology international</Title><ISOAbbreviation>Rheumatol Int</ISOAbbreviation></Journal><ArticleTitle>A systematic review of the incidence, management and prognosis of new-onset autoimmune connective tissue diseases after COVID-19.</ArticleTitle><Pagination><StartPage>1221</StartPage><EndPage>1243</EndPage><MedlinePgn>1221-1243</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00296-023-05283-9</ELocationID><Abstract><AbstractText>A literature review on new-onset autoimmune connective tissue diseases (ACTDs) following COVID-19 is lacking. We evaluated potential associations between COVID-19 and the development of new-onset ACTDs. The "population" was adults with disease terms for ACTDs, including systemic lupus erythematosus (SLE), Sjogren's syndrome, systemic sclerosis (SSc), idiopathic inflammatory myositis (IIM), anti-synthetase syndrome, mixed CTD and undifferentiated CTD, and "intervention" as COVID-19 and related terms. Databases were searched for English-language articles published until September 2022. We identified 2236 articles with 28 ultimately included. Of the 28 included patients, 64.3% were female, with a mean age was 51.1&#xa0;years. The USA reported the most cases (9/28). ACTD diagnoses comprised: 11 (39.3%) IIM (including four dermatomyositis); 7 (25%) SLE; four (14.3%) anti-synthetase syndrome; four (14.3%) SSc; two (7.1%) other ACTD (one lupus/MCTD overlap). Of eight, four (14.3%) patients (including that with lupus/MCTD) had lupus nephritis. The average time from COVID-19 to ACTD diagnosis was 23.7&#xa0;days. A third of patients were admitted to critical care, one for treatment of haemophagocytic lymphohistiocytosis in SLE (14 sessions of plasmapheresis, rituximab and intravenous corticosteroids) and nine due to COVID-19. 80% of patients went into remission of ACTD following treatment, while three (10%) patients died-one due to macrophage activation syndrome with anti-synthetase syndrome and two from unreported causes. Our results suggest a potential association between COVID-19 and new-onset ACTDs, notably in young females, reflecting more comprehensive CTD epidemiology. The most common diagnosis in our cohort was IIM. The aetiology and mechanisms by which ACTDs emerge following COVID-19 remain unknown and require further research.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kouranloo</LastName><ForeName>Koushan</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0002-6276-137X</Identifier><AffiliationInfo><Affiliation>School of Medicine, University of Liverpool, Ashon St., Liverpool, L69 3GE, UK. k.kouranloo@doctors.net.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Royal Liverpool University NHS Foundation Trust, Prescot St., Liverpool, L7 8XP, UK. k.kouranloo@doctors.net.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dey</LastName><ForeName>Mrinalini</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Queen Elizabeth Hospital, Stadium Rd., London, SE18 4QH, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Life Health Sciences, University of Liverpool, Liverpool, L7 8TX, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elwell</LastName><ForeName>Helen</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>BMA Library, BMA House, Tavistock Square, British Medical Association, London, WC1H 9JP, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nune</LastName><ForeName>Arvind</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, Southport and Ormskirk NHS Foundation Trust, Southport, PR8 6PN, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rheumatol Int</MedlineTA><NlmUniqueID>8206885</NlmUniqueID><ISSNLinking>0172-8172</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008947" MajorTopicYN="Y">Mixed Connective Tissue Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003240" MajorTopicYN="Y">Connective Tissue Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="Y">Autoimmune Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012595" MajorTopicYN="Y">Scleroderma, Systemic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009220" MajorTopicYN="Y">Myositis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune connective tissue diseases</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Pandemic</Keyword><Keyword MajorTopicYN="N">Rheumatic disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors (KK, MD, HE, AN) declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>1</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>17</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>14</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36786873</ArticleId><ArticleId IdType="pmc">PMC9927056</ArticleId><ArticleId IdType="doi">10.1007/s00296-023-05283-9</ArticleId><ArticleId IdType="pii">10.1007/s00296-023-05283-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matta S, Chopra KK, Arora VK. Morbidity and mortality trends of Covid 19 in top 10 countries. Indian J Tuberc. 2020;67(4S):S167&#x2013;S172. doi: 10.1016/j.ijtb.2020.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijtb.2020.09.031</ArticleId><ArticleId IdType="pmc">PMC7543896</ArticleId><ArticleId IdType="pubmed">33308665</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Coronavirus (COVID-19) dashboard | WHO Coronavirus (COVID-19) dashboard with vaccination data. https://covid19.who.int/?mapFilter=deaths.</Citation></Reference><Reference><Citation>Caso F, Costa L, Ruscitti P, Navarini L, Del Puente A, Giacomelli R, et al. Could Sars-coronavirus-2 trigger autoimmune and/or autoinflammatory mechanisms in genetically predisposed subjects? Autoimmun Rev. 2020;19(5):102524. doi: 10.1016/j.autrev.2020.102524.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102524</ArticleId><ArticleId IdType="pmc">PMC7271072</ArticleId><ArticleId IdType="pubmed">32220633</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155&#x2013;162. doi: 10.1097/BOR.0000000000000776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0000000000000776</ArticleId><ArticleId IdType="pmc">PMC7880581</ArticleId><ArticleId IdType="pubmed">33332890</ArticleId></ArticleIdList></Reference><Reference><Citation>Yazdanpanah N, Rezaei N. Autoimmune complications of COVID-19. J Med Virol. 2022;94(1):54&#x2013;62. doi: 10.1002/jmv.27292.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27292</ArticleId><ArticleId IdType="pmc">PMC8661629</ArticleId><ArticleId IdType="pubmed">34427929</ArticleId></ArticleIdList></Reference><Reference><Citation>Dotan A, Muller S, Kanduc D, David P, Halpert G, Shoenfeld Y. The SARS-CoV-2 as an instrumental trigger of autoimmunity. Autoimmun Rev. 2021;20(4):102792. doi: 10.1016/j.autrev.2021.102792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102792</ArticleId><ArticleId IdType="pmc">PMC7892316</ArticleId><ArticleId IdType="pubmed">33610751</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16(8):413&#x2013;414. doi: 10.1038/s41584-020-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0448-7</ArticleId><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference><Reference><Citation>Saad MA, Alfishawy M, Nassar M, Mohamed M, Esene IN, Elbendary A. COVID-19 and autoimmune diseases: a systematic review of reported cases. Curr Rheumatol Rev. 2021;17(2):193&#x2013;204.</Citation><ArticleIdList><ArticleId IdType="pubmed">33121413</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang KT, Hsu BC, Chen DY. Autoimmune and rheumatic manifestations associated with COVID-19 in adults: an updated systematic review. Front Immunol. 2021;12:645013. doi: 10.3389/fimmu.2021.645013.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.645013</ArticleId><ArticleId IdType="pmc">PMC7994612</ArticleId><ArticleId IdType="pubmed">33777042</ArticleId></ArticleIdList></Reference><Reference><Citation>Nune A, Iyengar KP, Mulherin D, Ish P, Musat CA, Sapkota HR. Granulomatosis with polyangiitis and COVID-19 pneumonia. Indian J Rheumatol. 2022;17(2):210&#x2013;212. doi: 10.4103/injr.injr_235_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/injr.injr_235_21</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaudhry ZS, Nellessen N, Reis C, Sharip A. The development of inflammatory arthritis following SARS-CoV-2 infection: a systematic review of the literature. Fam Pract. 2022 doi: 10.1093/fampra/cmac029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmac029</ArticleId><ArticleId IdType="pmc">PMC9383795</ArticleId><ArticleId IdType="pubmed">35395090</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong K, Farooq Alam Shah MU, Khurshid M, Ullah I, Tahir MJ, Yousaf Z. COVID-19 associated vasculitis: a systematic review of case reports and case series. Ann Med Surg. 2022;74:103249. doi: 10.1016/j.amsu.2022.103249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103249</ArticleId><ArticleId IdType="pmc">PMC8754903</ArticleId><ArticleId IdType="pubmed">35039779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cochrane Handbook for Systematic Reviews of Interventions | Cochrane Training. https://training.cochrane.org/handbook/current.</Citation></Reference><Reference><Citation>Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160. doi: 10.1136/bmj.n160.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n160</ArticleId><ArticleId IdType="pmc">PMC8005925</ArticleId><ArticleId IdType="pubmed">33781993</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Iorio M, Cook CE, Vanni KMM, Patel NJ, D&#x2019;Silva KM, Fu X, et al. DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective study. Semin Arthritis Rheum. 2022;55:152025. doi: 10.1016/j.semarthrit.2022.152025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2022.152025</ArticleId><ArticleId IdType="pmc">PMC9116968</ArticleId><ArticleId IdType="pubmed">35617780</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmed S, Zimba O, Gasparyan AY. COVID-19 and the clinical course of rheumatic manifestations. Clin Rheumatol. 2021;40(7):2611&#x2013;2619. doi: 10.1007/s10067-021-05691-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05691-x</ArticleId><ArticleId IdType="pmc">PMC7968918</ArticleId><ArticleId IdType="pubmed">33733315</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerma LA, Chaudhary A, Bryan A, Morishima C, Wener MH, Fink SL. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19) J Transl Autoimmun. 2020;3:100073. doi: 10.1016/j.jtauto.2020.100073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtauto.2020.100073</ArticleId><ArticleId IdType="pmc">PMC7691817</ArticleId><ArticleId IdType="pubmed">33263103</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033&#x2013;1034. doi: 10.1016/S0140-6736(20)30628-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30628-0</ArticleId><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Holzer MT, Krusche M, Ruffer N, Haberstock H, Stephan M, Huber TB, et al. New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review. Rheumatol Int. 2022;42(12):2267. doi: 10.1007/s00296-022-05176-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-022-05176-3</ArticleId><ArticleId IdType="pmc">PMC9358381</ArticleId><ArticleId IdType="pubmed">35939078</ArticleId></ArticleIdList></Reference><Reference><Citation>Borges NH, Godoy TM, Kahlow BS. Onset of dermatomyositis in close association with COVID-19-a first case reported. Rheumatology (Oxford) 2021;60(SI):SI96. doi: 10.1093/rheumatology/keab290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab290</ArticleId><ArticleId IdType="pmc">PMC8083658</ArticleId><ArticleId IdType="pubmed">33757122</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacchi MC, Tamiazzo S, Lauritano EC, Bonometti R. Case report of COVID-19 in an elderly patient: could SARS-CoV2 trigger myositis? Eur Rev Med Pharmacol Sci. 2020;24(22):11960&#x2013;11963.</Citation><ArticleIdList><ArticleId IdType="pubmed">33275270</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H, Charmchi Z, Seidman R, Anziska Y, Velayudhan V, Perk J (2022) COVID-19 associated myositis with severe proximal and bulbar weakness (P9-9.006). Neurology 98(18 Supplement)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7323133</ArticleId><ArticleId IdType="pubmed">32535934</ArticleId></ArticleIdList></Reference><Reference><Citation>Okayasu T, Ohta R, Igarashi M, Kurita Y, Hayakawa M, Sano C. Coexistence of pancytopenia and myositis after developing COVID-19. Cureus. 2022 doi: 10.7759/cureus.26978.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.26978</ArticleId><ArticleId IdType="pmc">PMC9385165</ArticleId><ArticleId IdType="pubmed">35989844</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada Y, Izumi R, Hosaka T, Watanabe S, Shijo T, Hatchome N, et al. Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy. Rheumatology (Oxford) 2022;61(4):E90&#x2013;E92. doi: 10.1093/rheumatology/keab872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab872</ArticleId><ArticleId IdType="pmc">PMC8690268</ArticleId><ArticleId IdType="pubmed">34850853</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahidi Dadras M, Rakhshan A, Ahmadzadeh A, Hosseini SA, Diab R, Safari Giv T, et al. Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: a new potential trigger for musculoskeletal autoimmune disease development. Clin Case Rep. 2021;9(10):e04931. doi: 10.1002/ccr3.4931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.4931</ArticleId><ArticleId IdType="pmc">PMC8512177</ArticleId><ArticleId IdType="pubmed">34667608</ArticleId></ArticleIdList></Reference><Reference><Citation>Assar S, Pournazari M, Soufivand P, Mohamadzadeh D. Successful treatment of COVID-19 induced neutrophilic myositis with intravenous immunoglobulin and corticosteroids: a case report. Reumatismo. 2022;73(4):232&#x2013;235. doi: 10.4081/reumatismo.2021.1437.</Citation><ArticleIdList><ArticleId IdType="doi">10.4081/reumatismo.2021.1437</ArticleId><ArticleId IdType="pubmed">35130685</ArticleId></ArticleIdList></Reference><Reference><Citation>Amin S, Rahim F, Noor M, Bangash A, Ghani F. Polymyositis: the comet tail after COVID-19. Cureus. 2022;14(6):e26453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9338774</ArticleId><ArticleId IdType="pubmed">35915688</ArticleId></ArticleIdList></Reference><Reference><Citation>Aldaghlawi F, Shammah A, Kio E. SARS-CoV-2 infection complicated with cold agglutinin disease and myositis. Clin Case Rep. 2021;9(4):2196&#x2013;2199. doi: 10.1002/ccr3.3981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ccr3.3981</ArticleId><ArticleId IdType="pmc">PMC8077249</ArticleId><ArticleId IdType="pubmed">33936663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lokineni S, Mortezavi M. Delayed-onset necrotizing myositis following COVID-19 infection. Eur J Case Rep Intern Med. 2021;8(4):002461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112084</ArticleId><ArticleId IdType="pubmed">33987125</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramachandran L, Dontaraju VS, Troyer J, Sahota J. New onset systemic lupus erythematosus after COVID-19 infection: a case report. AME Case Rep. 2022;6:14. doi: 10.21037/acr-21-55.</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/acr-21-55</ArticleId><ArticleId IdType="pmc">PMC9010314</ArticleId><ArticleId IdType="pubmed">35475008</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazzi B, Fine D, Geetha D, Chung M, Monroy-Trujillo M, Timlin H. New-onset lupus nephritis associated with COVID-19 infection. Lupus. 2022;31(8):1007&#x2013;1011. doi: 10.1177/09612033221098571.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033221098571</ArticleId><ArticleId IdType="pmc">PMC9066225</ArticleId><ArticleId IdType="pubmed">35485455</ArticleId></ArticleIdList></Reference><Reference><Citation>Assar S, Pournazari M, Soufivand P, Mohamadzadeh D. Systemic lupus erythematosus after coronavirus disease-2019 (COVID-19) infection: case-based review. Egypt Rheumatol. 2022;44(2):145&#x2013;149. doi: 10.1016/j.ejr.2021.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejr.2021.08.013</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali S, Almas T, Zaidi U, Ahmed F, Shaikh S, Shaikh F, et al. A novel case of lupus nephritis and mixed connective tissue disorder in a COVID-19 patient. Ann Med Surg. 2022;78:103653. doi: 10.1016/j.amsu.2022.103653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amsu.2022.103653</ArticleId><ArticleId IdType="pmc">PMC9034828</ArticleId><ArticleId IdType="pubmed">35495962</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamani B, Moeini Taba SM, Shayestehpour M. Systemic lupus erythematosus manifestation following COVID-19: a case report. J Med Case Rep. 2021;15(1):1&#x2013;4. doi: 10.1186/s13256-020-02582-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13256-020-02582-8</ArticleId><ArticleId IdType="pmc">PMC7832415</ArticleId><ArticleId IdType="pubmed">33494816</ArticleId></ArticleIdList></Reference><Reference><Citation>Slimani Y, Abbassi R, El Fatoiki FZ, Barrou L, Chiheb S. Systemic lupus erythematosus and varicella-like rash following COVID-19 in a previously healthy patient. J Med Virol. 2021;93(2):1184&#x2013;1187. doi: 10.1002/jmv.26513.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26513</ArticleId><ArticleId IdType="pubmed">32926434</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali R, Mehannek R, Patel A, Paige A, Reddy S, Guma M, et al. Systemic lupus erythematosus with hemophagocytic lymphohistiocytosis: is COVID-19 the inciting factor? Cureus. 2021;13(11):e19657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8679171</ArticleId><ArticleId IdType="pubmed">34976453</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonometti R, Sacchi MC, Stobbione P, Lauritano EC, Tamiazzo S, Marchegiani A, et al. The first case of systemic lupus erythematosus (SLE) triggered by COVID-19 infection. Eur Rev Med Pharmacol Sci. 2020;24(18):9695&#x2013;9697.</Citation><ArticleIdList><ArticleId IdType="pubmed">33015814</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunes AL, Simoes L, Figueiredo C, Carvalho R, Lima J, Santos RM. Toxic epidermal necrolysis-like lupus erythematous presentation following SARS-CoV-2 infection. J Med Cases. 2022;13(2):89&#x2013;93. doi: 10.14740/jmc3880.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jmc3880</ArticleId><ArticleId IdType="pmc">PMC8913004</ArticleId><ArticleId IdType="pubmed">35317091</ArticleId></ArticleIdList></Reference><Reference><Citation>Farisogullari B, Pinto AS, Machado PM. COVID-19-associated arthritis: an emerging new entity? RMD Open. 2022;8(2):e002026. doi: 10.1136/rmdopen-2021-002026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-002026</ArticleId><ArticleId IdType="pmc">PMC9471208</ArticleId><ArticleId IdType="pubmed">36100294</ArticleId></ArticleIdList></Reference><Reference><Citation>Pereira M, Shivdasani D, Roy D, Rungta R, Dang S, Singh N. Post-COVID-19 unusual inflammatory syndromes detected on 18F-FDG PET/CT scan. Clin Nucl Med. 2022;47(4):E363&#x2013;E365. doi: 10.1097/RLU.0000000000004088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/RLU.0000000000004088</ArticleId><ArticleId IdType="pmc">PMC8884126</ArticleId><ArticleId IdType="pubmed">35119395</ArticleId></ArticleIdList></Reference><Reference><Citation>Giuggioli D, Spinella A, de Pinto M, Mascia MT, Salvarani C. From Raynaud phenomenon to systemic sclerosis in COVID-19: a case report. Adv Skin Wound Care. 2022;35(2):123&#x2013;124. doi: 10.1097/01.ASW.0000795240.63966.53.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASW.0000795240.63966.53</ArticleId><ArticleId IdType="pubmed">34629385</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandra A, Kahaleh B. Systemic sclerosis (SSc) after COVID-19: a case report. Cureus. 2022;14(3):e23179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9009972</ArticleId><ArticleId IdType="pubmed">35444873</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouchard Marmen M, Ellezam B, Fritzler MJ, Troyanov Y, Gould PV, Satoh M, et al. Anti-synthetase syndrome occurring after SARS-CoV-2 infection. Scand J Rheumatol. 2022;51(3):255&#x2013;257. doi: 10.1080/03009742.2021.2024019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2021.2024019</ArticleId><ArticleId IdType="pubmed">35138215</ArticleId></ArticleIdList></Reference><Reference><Citation>Blum FR, Sampath AJ, Gilbert AL, Foulke GT. Diffuse systemic sclerosis following COVID-19 infection. Scand J Rheumatol. 2022 doi: 10.1080/03009742.2022.2103935.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/03009742.2022.2103935</ArticleId><ArticleId IdType="pubmed">35946910</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderle K, Machold K, Kiener HP, Bormann D, Hoetzenecker K, Geleff S, et al. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. BMC Rheumatol. 2022 doi: 10.1186/s41927-022-00271-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-022-00271-1</ArticleId><ArticleId IdType="pmc">PMC9277832</ArticleId><ArticleId IdType="pubmed">35821079</ArticleId></ArticleIdList></Reference><Reference><Citation>Keshtkarjahromi M, Chhetri S, Balagani A, et al. Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection. BMC Rheumatol. 2021;5(1):59. doi: 10.1186/s41927-021-00225-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41927-021-00225-z</ArticleId><ArticleId IdType="pmc">PMC8666190</ArticleId><ArticleId IdType="pubmed">34895325</ArticleId></ArticleIdList></Reference><Reference><Citation>Fineschi S. Case report: systemic sclerosis after Covid-19 infection. Front Immunol. 2021;12:2439. doi: 10.3389/fimmu.2021.686699.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.686699</ArticleId><ArticleId IdType="pmc">PMC8273695</ArticleId><ArticleId IdType="pubmed">34262566</ArticleId></ArticleIdList></Reference><Reference><Citation>Galeotti C, Bayry J. Autoimmune and inflammatory diseases following COVID-19. Nat Rev Rheumatol. 2020;16:413&#x2013;414. doi: 10.1038/s41584-020-0448-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-020-0448-7</ArticleId><ArticleId IdType="pmc">PMC7271827</ArticleId><ArticleId IdType="pubmed">32499548</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>